Biotech Values

[DewDiligence]

Re: “Community” vs “academic” management of AEs

Did you make anything of Dr. Diab's comments about academic centers managing AE's better and getting higher responses or is that a generalization that can be applied to most new immuno-oncology therapies?

This is true for oncology in general, in my experience.

Dr. Diab gave a practical explanation for the disparity: “community” oncologists have to go out of their way, literally, to treat hospitalized patients; academic oncologists, on the other hand, are working in a hospital setting all the time, and hence managing AEs for hospitalized patients is not unduly burdensome.